Athira Pharma Competitors

Sorrento Therapeutics (NASDAQ:SRNE) and Athira Pharma (NASDAQ:ATHA) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, institutional ownership, analyst recommendations, dividends, valuation, earnings and profitability.

Profitability

This table compares Sorrento Therapeutics and Athira Pharma's net margins, return on equity and return on assets.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Sorrento Therapeutics and Athira Pharma, as reported by MarketBeat.

Sorrento Therapeutics currently has a consensus price target of $28.75, indicating a potential upside of 226.33%. Athira Pharma has a consensus price target of $42.50, indicating a potential upside of 120.32%. Given Sorrento Therapeutics' higher probable upside, analysts clearly believe Sorrento Therapeutics is more favorable than Athira Pharma.

Institutional and Insider Ownership

27.4% of Sorrento Therapeutics shares are owned by institutional investors. Comparatively, 66.7% of Athira Pharma shares are owned by institutional investors. 3.4% of Sorrento Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Sorrento Therapeutics and Athira Pharma's top-line revenue, earnings per share (EPS) and valuation.

Athira Pharma has lower revenue, but higher earnings than Sorrento Therapeutics.

Summary

Athira Pharma beats Sorrento Therapeutics on 5 of the 8 factors compared between the two stocks.

Athira Pharma (NASDAQ:ATHA) and AlloVir (NASDAQ:ALVR) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, earnings, profitability, risk and valuation.

Analyst Recommendations

This is a summary of recent ratings for Athira Pharma and AlloVir, as reported by MarketBeat.com.

Athira Pharma currently has a consensus price target of $42.50, indicating a potential upside of 120.32%. AlloVir has a consensus price target of $48.75, indicating a potential upside of 41.18%. Given Athira Pharma's higher probable upside, equities research analysts plainly believe Athira Pharma is more favorable than AlloVir.

Valuation and Earnings

This table compares Athira Pharma and AlloVir's top-line revenue, earnings per share (EPS) and valuation.

Profitability

This table compares Athira Pharma and AlloVir's net margins, return on equity and return on assets.

Institutional & Insider Ownership

66.7% of Athira Pharma shares are owned by institutional investors. Comparatively, 32.1% of AlloVir shares are owned by institutional investors. 1.0% of AlloVir shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Athira Pharma beats AlloVir on 2 of the 3 factors compared between the two stocks.

Kymera Therapeutics (NASDAQ:KYMR) and Athira Pharma (NASDAQ:ATHA) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, profitability, dividends, analyst recommendations, valuation, risk and institutional ownership.

Profitability

This table compares Kymera Therapeutics and Athira Pharma's net margins, return on equity and return on assets.

Institutional & Insider Ownership

37.8% of Kymera Therapeutics shares are owned by institutional investors. Comparatively, 66.7% of Athira Pharma shares are owned by institutional investors. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Valuation & Earnings

This table compares Kymera Therapeutics and Athira Pharma's gross revenue, earnings per share and valuation.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Kymera Therapeutics and Athira Pharma, as reported by MarketBeat.

Kymera Therapeutics currently has a consensus target price of $50.3333, indicating a potential upside of 9.75%. Athira Pharma has a consensus target price of $42.50, indicating a potential upside of 120.32%. Given Athira Pharma's stronger consensus rating and higher possible upside, analysts plainly believe Athira Pharma is more favorable than Kymera Therapeutics.

Summary

Athira Pharma beats Kymera Therapeutics on 3 of the 3 factors compared between the two stocks.

BioCryst Pharmaceuticals (NASDAQ:BCRX) and Athira Pharma (NASDAQ:ATHA) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, dividends, profitability, institutional ownership, risk, analyst recommendations and valuation.

Profitability

This table compares BioCryst Pharmaceuticals and Athira Pharma's net margins, return on equity and return on assets.

Valuation & Earnings

This table compares BioCryst Pharmaceuticals and Athira Pharma's top-line revenue, earnings per share (EPS) and valuation.

Athira Pharma has lower revenue, but higher earnings than BioCryst Pharmaceuticals.

Analyst Recommendations

This is a summary of recent ratings and target prices for BioCryst Pharmaceuticals and Athira Pharma, as reported by MarketBeat.

BioCryst Pharmaceuticals presently has a consensus target price of $11.3750, suggesting a potential upside of 4.17%. Athira Pharma has a consensus target price of $42.50, suggesting a potential upside of 120.32%. Given Athira Pharma's stronger consensus rating and higher probable upside, analysts plainly believe Athira Pharma is more favorable than BioCryst Pharmaceuticals.

Insider & Institutional Ownership

72.0% of BioCryst Pharmaceuticals shares are owned by institutional investors. Comparatively, 66.7% of Athira Pharma shares are owned by institutional investors. 4.3% of BioCryst Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Athira Pharma beats BioCryst Pharmaceuticals on 6 of the 10 factors compared between the two stocks.

bluebird bio (NASDAQ:BLUE) and Athira Pharma (NASDAQ:ATHA) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, institutional ownership, dividends, valuation, earnings, profitability and analyst recommendations.

Profitability

This table compares bluebird bio and Athira Pharma's net margins, return on equity and return on assets.

Earnings and Valuation

This table compares bluebird bio and Athira Pharma's revenue, earnings per share (EPS) and valuation.

Athira Pharma has lower revenue, but higher earnings than bluebird bio.

Analyst Ratings

This is a breakdown of current ratings for bluebird bio and Athira Pharma, as provided by MarketBeat.

bluebird bio presently has a consensus price target of $68.4667, suggesting a potential upside of 145.05%. Athira Pharma has a consensus price target of $42.50, suggesting a potential upside of 120.32%. Given bluebird bio's higher probable upside, equities research analysts plainly believe bluebird bio is more favorable than Athira Pharma.

Insider & Institutional Ownership

94.3% of bluebird bio shares are held by institutional investors. Comparatively, 66.7% of Athira Pharma shares are held by institutional investors. 3.6% of bluebird bio shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Athira Pharma beats bluebird bio on 5 of the 9 factors compared between the two stocks.

Vericel (NASDAQ:VCEL) and Athira Pharma (NASDAQ:ATHA) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, dividends, profitability, earnings, analyst recommendations, risk and valuation.

Profitability

This table compares Vericel and Athira Pharma's net margins, return on equity and return on assets.

Earnings & Valuation

This table compares Vericel and Athira Pharma's revenue, earnings per share (EPS) and valuation.

Athira Pharma has lower revenue, but higher earnings than Vericel.

Analyst Recommendations

This is a summary of current recommendations and price targets for Vericel and Athira Pharma, as provided by MarketBeat.com.

Vericel presently has a consensus target price of $49.00, suggesting a potential upside of 21.26%. Athira Pharma has a consensus target price of $42.50, suggesting a potential upside of 120.32%. Given Athira Pharma's stronger consensus rating and higher probable upside, analysts clearly believe Athira Pharma is more favorable than Vericel.

Insider and Institutional Ownership

93.1% of Vericel shares are owned by institutional investors. Comparatively, 66.7% of Athira Pharma shares are owned by institutional investors. 4.3% of Vericel shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Vericel beats Athira Pharma on 7 of the 10 factors compared between the two stocks.